Citius Pharmaceuticals is a biopharmaceutical company that develops and commercializes critical care products addressing unmet medical needs in oncology, anti-infective treatments for cancer patients, and other specialized therapeutic areas, focusing on lower-development-risk approaches such as new formulations of previously approved drugs. The company generates revenue primarily through its commercial subsidiary Citius Oncology, which sells LYMPHIR, an FDA-approved targeted therapy for cutaneous T-cell lymphoma, via third-party sales organizations and established pharmaceutical distributors, while also maintaining a pipeline of late-stage candidates including Mino-Lok for catheter-related infections and Halo-Lido for hemorrhoids that it plans to commercialize or partner. Citius targets niche markets with substantial patient populations and unmet therapeutic needs—such as the U.S. cutaneous lymphoma market exceeding $400 million and the catheter infection market ranging from $500 million to $1 billion—by pursuing regulatory exclusivity and leveraging key opinion leader relationships to establish leading positions in these specialized segments.